Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib. This is a Phase 1,
open-label, dose-escalation, dose-expansion, safety, pharmacokinetics, and pharmacodynamic
study, with a purpose of determining the maximum tolerated dose (MTD) and dose-limiting
toxicities (DLTs) of oral TP-1287 in patients with advanced metastatic or progressive solid
tumors who are refractory to, or intolerant of, established therapy known to provide clinical
benefit for their condition.
Phase:
Phase 1
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Oncology, Inc Tolero Pharmaceuticals, Inc.